CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
Levetiracetam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03034356
NCT03034356Phase 2Completed
CompareCT.gov

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

VA Office of Research and Development·interventional·Posted Jan 27, 2017·Updated Jul 14, 2025

In Brief

A Phase 2 clinical trial evaluating Levetiracetam and Placebo for Schizophrenia. Completed, enrolled 67 participants across 1 site.

Detailed Summary

This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 27, 2017
Enrollment StartSep 1, 2018
Primary CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 9.4 years ago

Interventions

Levetiracetamdrug

Anticonvulsant drug

Placebodrug

Placebo